244. Development, Qualification, and Clinical Validation of an Immunodiagnostic assay for the Detection of 11 Additional S. pneumoniae Serotype-Specific Polysaccharides in Human Urine
Warren V. Kalina(Pfizer (United States)), Michael W. Pride(Pfizer (United States)), Donna Giordano-Schmidt(Pfizer (United States)), Victor Costa de Souza(Pfizer (United States)), Charles Y. Tan(United States Military Academy), Huiming Cheng(Pfizer (United States)), Kangjian Wu(Pfizer (United States)), Manu Unnithan(Pfizer (United States)), Andrew McKeen(Pfizer (United States)), Kelly A. Belanger(Pfizer (United States)), Peter C. Giardina(Pfizer (United States)), Bradford D. Gessner(Pfizer (United States)), Kathrin U. Jansen(Pfizer (United States)), Sue McElhiney(Pfizer (United States)), Qin Jiang(Pfizer (United States)), Yanhua Ren(Pfizer (United States))
Cited by 0
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
The Global Burden of Cancer 2013
|JAMA Oncology|2015|2.8k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k